Table 3.

Summary of AEs

	Cohort, n (%)
	45 mg (n = 94)	30 mg (n = 94)	15 mg (n = 94)
TEAEs
Any TEAE	94 (100)	88 (93.6)	89 (94.7)
Grade ≥3 TEAEs	64 (68.1)	58 (61.7)	60 (63.8)
Serious TEAEs	32 (34)	24 (25.5)	31 (33.0)
Grade 5 TEAEs	2 (2.1)	0	2 (2.1)
Dose modifications for TEAEs
Discontinuation	18 (19.1)	15 (16.0)	13 (13.8)
Reduction	43 (45.7)	33 (35.1)	30 (31.9)
Interruption	67 (71.3)	58 (61.7)	55 (58.5)
TE-AOEs
Any AOE	9 (9.6)	5 (5.3)	3 (3.2)
Serious TE-AOEs	4 (4.3)	4 (4.3)	3 (3.2)
Grade ≥3 TE-AOEs	5 (5.3)	5 (5.3)	3 (3.2)
Dose modifications for AOE
Discontinuation	4 (4.3)	3 (3.2)	1 (1.1)
Reduction	0	1 (1.1)	0
Interruption	2 (2.1)	3 (3.2)	1 (1.1)